Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma

British Journal of Haematology

Volumn 160, Issue 1, 2013, Pages 111-114

  Popat, Rakesh ^a   Maharaj, Lenushka ^a,b   Oakervee, Heather ^c   Cavenagh, Jamie ^c   Joel, Simon ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Multiple myeloma; Myeloma therapy; Pharmacology

Indexed keywords

BORTEZOMIB; MELPHALAN;

APOPTOSIS; BONE MARROW CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL VIABILITY; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENTIATION; HUMAN; HUMAN CELL; LETTER; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; HUMANS; MELPHALAN; MULTIPLE MYELOMA; PYRAZINES;

EID: 84870772024     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12089     Document Type: Letter

References (10)

1. Chou, T.C. & Talalay, P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 27-55.
2. Fahy, B.N., Schlieman, M.G., Virudachalam, S. & Bold, R.J. (2003) Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. Journal of Surgical Research, 113, 88-95.
3. Lonial, S., Kaufman, J., Tighiouart, M., Nooka, A., Langston, A.A., Heffner, L.T., Torre, C., McMillan, S., Renfroe, H., Harvey, R.D., Lechowicz, M.J., Khoury, H.J., Flowers, C.R. & Waller, E.K. (2010) A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clinical Cancer Research, 16, 5079-5086.
4. Mitsiades, N., Mitsiades, C.S., Richardson, P.G., Poulaki, V., Tai, Y.T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Schlossman, R., Munshi, N.C., Hideshima, T. & Anderson, K.C. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood, 101, 2377-2380.
5. Nencioni, A., Hua, F., Dillon, C.P., Yokoo, R., Scheiermann, C., Cardone, M.H., Barbieri, E., Rocco, I., Garuti, A., Wesselborg, S., Belka, C., Brossart, P., Patrone, F. & Ballestrero, A. (2005) Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood, 105, 3255-3262.
6. Popat, R., Oakervee, H., Williams, C., Cook, M., Craddock, C., Basu, S., Singer, C., Harding, S., Foot, N., Hallam, S., Odeh, L., Joel, S. & Cavenagh, J. (2009) Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. British Journal of Haematology, 144, 887-894.
7. San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmoszynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.V., Anderson, K.C., Esseltine, D.L., Liu, K., Cakana, A., van de Velde, H. & Richardson, P.G. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359, 906-917.
8. Spanswick, V.J., Craddock, C., Sekhar, M., Mahendra, P., Shankaranarayana, P., Hughes, R.G., Hochhauser, D. & Hartley, J.A. (2002) Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood, 100, 224-229.
9. Weigert, O., Pastore, A., Rieken, M., Lang, N., Hiddemann, W. & Dreyling, M. (2007) Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia, 21, 524-528.
10. Yarde, D.N., Oliveira, V., Mathews, L., Wang, X., Villagra, A., Boulware, D., Shain, K.H., Hazlehurst, L.A., Alsina, M., Chen, D.T., Beg, A.A. & Dalton, W.S. (2009) Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Research, 69, 9367-9937.